Healius rallies after sealing Lumus Imaging sale
Make us a preferred source
Make us a preferred source on Google
The news: Pathology services provider Healius was one of the best performing ASX 200 companies on Thursday afternoon after completing the sale of its Lumus Imaging subsidiary to funds managed by Asian private equity firm Affinity Equity Partners.
The numbers: Healius shares were up 4.5% to $1.52 at 2:45pm AEST, having advanced more than 30% over the last 12 months.
The company said it has received cash proceeds of $822 million from the sale, representing an enterprise value of $965 million for the sold business.
Healius intends to pay a special dividend of 41.3 cents per share, totalling $300 million.
What they said: "The sale of Lumus resets Healius' balance sheet and allows the business to focus on executing our pathology strategy by providing better services for our patients and referrers," said Healius managing director and CEO Paul Anderson.
"With the simplification of our operations, we will also be in a position to streamline the corporate cost base."
The source: ASX
